Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omeganol is a multi-ingredient dietary supplement formulated to support cardiovascular health and lipid metabolism. Its primary active ingredients typically include omega-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid), allicin (derived from garlic extract), and fat-soluble vitamins such as Vitamin E and Vitamin A. The omega-3 components function as ligands for peroxisome proliferator-activated receptors (PPARs), particularly PPAR-alpha, leading to reduced triglyceride synthesis and improved lipid profiles. Allicin contributes antioxidant properties and may help inhibit cholesterol biosynthesis, while Vitamin E protects cell membranes from oxidative damage. It is primarily indicated for the prevention of atherosclerosis and the management of hyperlipidemia, and it is widely marketed in Eastern European and Russian markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Omeganol.